Understanding patient preferences and willingness to pay for hemophilia therapies

BACKGROUND: Despite clearly improved clinical outcomes for prophylaxis compared to on-demand therapy, on average only 56% of patients diagnosed with severe hemophilia receive prophylactic factor replacement therapy in the US. Prophylaxis rates generally drop as patients transition from childhood to...

Descripción completa

Detalles Bibliográficos
Autores principales: Chaugule, Shraddha S, Hay, Joel W, Young, Guy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4646600/
https://www.ncbi.nlm.nih.gov/pubmed/26635471
http://dx.doi.org/10.2147/PPA.S92985

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4646600/
https://www.ncbi.nlm.nih.gov/pubmed/26635471
http://dx.doi.org/10.2147/PPA.S92985

Ejemplares similares